Bioinformatic analysis of the expression and prognosis of ZNF589 in human breast cancer

Jun Fan1#, Zhe Zhang1, Dongjiao Chen2,3, Hongqiang Chen2, Wenbo Yuan2,4, Lu Zhou1, Jing Xu1, Wenbin Liu1, Yan Xu1^*

1Department of Breast and Thyroid Surgery, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing, China; 2Institute of Toxicology, College of Preventive Medicine, Army Medical University (Third Military Medical University), Chongqing, China; 3College of Public Health and Management, Ningxia Medical University, Yinchuan, China; 4School of Public Health, Xinxiang Medical University, Xinxiang, China

Contributions: (I) Conception and design: J Fan, Z Zhang; (II) Administrative support: W Liu, Y Xu; (III) Provision of study materials or patients: D Chen, H Chen, W Yuan, L Zhou, J Xu; (IV) Collection and assembly of data: J Fan, Z Zhang; (V) Data analysis and interpretation: J Fan, Z Zhang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

# These authors contributed equally to this work.

^ Correspondence to: Wenbin Liu. Institute of Toxicology, College of Preventive Medicine, Army Medical University (Third Military Medical University), Chongqing 400038, China. Email: liuwenbin@tmmu.edu.cn; Yan Xu. Department of Breast and Thyroid Surgery, Daping Hospital, Army Medical University (Third Military Medical University), Chongqing 400042, China. Email: xy931@163.com.

Background: Zinc finger protein 589 (ZNF589) is a member of the zinc finger protein (ZNF) family and plays an important role in the differentiation of haemopoietic system stem cells. However, its effects on tumorigenesis and progression have not yet been reported. The purpose of this study was to explore the prognosis and underlying mechanism of ZNF589 in breast cancer (BRCA) through a bioinformatic analysis.

Methods: ZNF589 transcription levels in a TCGA BC cohort were analysed and then validated using Oncomine and UALCAN. The prognostic value of ZNF589 was determined based on the overall survival (OS) and relapse-free survival (RFS) based on The Cancer Genome Atlas (TCGA) cohort and Kaplan-Meier (K-M) database. LinkedOmics and STRING were carried out to explore the potential co-expressed genes and interactive proteins as well as corresponding enrichment analysis. A Gene Set Enrichment Analysis (GSEA) was performed between two gene matrices separated by the median cut-off value of ZNF589. The methylation levels of the ZNF589 promoter were analysed using UALCAN.

Results: ZNF589 was downregulated in breast tumours, and lower expression was associated with poor OS (P=0.047) and RFS (P=0.0043) according to TCGA. A subgroup analysis showed that the downregulation of ZNF589 was significantly associated with poor OS in stage 3–4 patients (P=0.0249) and progesterone receptor (PR)-negative patients (P=0.0002). Consistently, lower ZNF589 predicted poor RFS in stage 3–4 patients (P=0.0090), hormone receptor-negative patients [oestrogen receptor (ER)-, P=0.0129; PR-, P=0.0130; human epidermal growth factor receptor 2 (HER2)-, P<0.0001] and triple-negative BRCA patients (P=0.0052). Univariate and multivariate Cox regressions indicated that ZNF589 could act as an independent prognostic biomarker for OS based on age and TNM stage. Functional enrichment analysis of co-expressed genes and a protein-protein interaction (PPI) network both suggested that ZNF589 expression was negatively correlated with cell cycle progression at the transcriptional and protein-interactive levels. Finally, we found that the downregulation of ZNF589 correlated with promoter hypermethylation, and the corresponding subgroup analysis presented similar results.

Conclusions: Our study highlighted that ZNF589 could act as a potential prognostic biomarker and a tumour suppressor in BRCA. A functional enrichment analysis suggested that ZNF589 may participate in multiple cancer-related pathways, including the cell cycle. Epigenetic factor promoter methylation could...
Introduction

Breast cancer (BRCA) is the most common type of solid tumour in female cancer patients. The incidence of BRCA varies broadly worldwide and ranges from 27/1,000,002 in Central-East Asia and Africa to 85–94/1,000,002 in Australia, North America and Western Europe (1). The increasing incidence of BRCA has led to the development of an increasing number of choices for diagnosis and therapy. Along with classical biomarkers, such as oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), cytokeratin (CK) and the breast cancer 1 (BRCA1) protein, a number of biomarkers of single genes or multigene features have been approved for clinical use for BRCA prognosis. For single genes, hormone receptors, BRCA1/2 and Ki-67 have already been used for pathological reports and molecular subtypes. For multigenes, MammaPrint and Prosigna are newly developed detection methods. Improving the surgical methods and developing more precise radiation therapy and targeted chemotherapy have been well reported as traditional methods, while immunotherapy represents a revolutionary development among the therapeutic methods for BRCA (2). However, almost 12% of BRCA patients eventually develop recurrent or metastatic BRCA, and the prognosis is poor in such patients, and even patients with the same subtype show heterogeneity in prognosis and chemical resistance (3). For example, locally advanced BRCA consists of terminal-stage primary tumours, cancers with extensive lymphatic metastasis and inflammatory BRCA, and it remains a difficult clinical problem in developing countries. Prevention and treatment techniques for locally advanced BRCA have not been developed, and well-coordinated treatment and superior biomarkers remain to be discovered (4). Therefore, the lack of biomarkers with high accuracy, specificity and convenient application is an important issue to be resolved in clinical medicine.

According to the expression data of the TCGA BC cohort, we found that many genes were significantly differentially expressed between normal and BRCA patients, including zinc finger protein 589 (ZNF589), also known as stem cell ZNF1. A study of haematopoietic stem/progenitor cells indicated the possible role of ZNF589 in the differentiation of CD34+ stem cells (5). Cys2-His2 (C2H2)-type zinc finger proteins (ZNFs) are a well-known family of transcription factors and nuclear hormone receptors. Characterized by zinc finger motifs, which are small peptide domains with a secondary structure stabilized by a zinc ion bound to the cysteine and/or histidine residues of the finger, ZNFs play versatile and crucial roles in various biological processes, including development, differentiation, metabolism, autophagy, atrophy, senescence, epithelial-mesenchymal transition (EMT) and apoptosis (6-11). Characterized by an N-terminal Krüppel-associated box domain and a C-terminal array of zinc-finger motifs, Krüppel-associated box (KRAB) domain zinc finger proteins (KZFPs) are the largest subfamily of C2H2-type ZNFs, the largest family of transcriptional regulators in eukaryotes (6,12). KRAB-ZFPs bind to DNA through their tandem zinc finger motifs to act as transcriptional repressors, and gene silencing is conducted by the highly conserved KRAB domain, which recruits histone deacetylase complexes, histone methylases, and heterochromatin proteins (13). Working together with their cofactor tripartite motif protein 28 (TRIM28), KZFPs participate in the transcriptional repression of multiple aspects of development and physiology (14). Even though the remarkable biological features of most KZFPs remain unclear, recent reports have suggested their role in differentiation, cell proliferation, apoptosis and EMT (14-17). According to the first report of ZNF589, it encodes a protein containing C2H2-type zinc fingers and a Krüppel-associated box domain. In the last decade, ZNF589 was sporadically reported in the fields of neurobiology, stem cell biology, immunology and cardiology (13,14,18-21). For oncology, only one report provided a prognostic signature analysis in squamous cell lung carcinoma in The Cancer Genome Atlas (TCGA) database and mentioned stem cell
ZNF1 in a 14-gene cluster (22). Thus, ZNF589 may play a role in prognosis in lung cancer. The distinct biological functions of ZNF589 in cancer, especially BRCA, have rarely been reported. Considering the lack of additional biomarkers with high accuracy, specificity and convenience for BRCA diagnosis, therapy and prognosis in clinical medicine as well as the obvious expression differences in the TCGA BC cohort and prognosis in previous bioinformatic preanalyses, this study set out to determine the predictive validity of ZNF589 in BRCA. The study presented here is the first investigation to survey the expression and clinical significance of ZNF589 in BRCA oncogenesis.

We present the following article in accordance with the REMARK reporting checklist (available at http://dx.doi.org/10.21037/tcr-20-3166).

**Methods**

First, we used the TCGA, Oncomine and UALCAN to assess the expression of ZNF589. Second, we obtained the survival curve from the Kaplan-Meier (K-M) plotter database and TCGA data collection to assess the prognostic value of ZNF589. To predict the reason for the expressional change in ZNF589, the methylation status of the ZNF589 promoter region and the gene alteration rate (mutation, copy number alteration and so on) of ZNF589 were estimated through UALCAN and cBioPortal, respectively. In terms of related gene and biological process prediction, STRING was used to predict proteins that interact with ZNF589. LinkedOmics was used to identify co-expressing genes with ZNF589. We put these related genes and proteins into their own enrichment modules and used DAVID to obtain the related biological processes and Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013), and this work did not require a statement on obtaining ethical approval because all data were obtained from public databases.

**TCGA data collection**

TCGA datasets contain sequencing and pathological data on 30 different types of cancers (23). mRNA expression (HiSeqV2) data were obtained from 133 normal samples and 1108 tumour samples. A total of 1108 tumour samples with clinical information were used to assess the prognostic value. The following corresponding clinical characteristics were extracted: age, sex, primary tumour status, regional lymph node status, TNM stage based on the American Joint Committee on Cancer (AJCC), ER status, PR status, HER2 status and histopathologic type. To analyse the overall survival (OS) and relapse-free survival (RFS) of BRCA patients, high- and low-expression groups were differentiated by the median cut-off of ZNF589 expression from 1108 samples and assessed by a K-M survival plot. We used univariate and multivariate Cox proportional hazard regression models to model the prognostic value of ZNF589 for OS and RFS. Age, sex, tumour infiltration, regional lymph node status, TNM stage, ER, PR, HER2 status and histopathologic type were analysed in regression models.

**Oncomine**

The Oncomine (https://www.oncomine.org/resource/login.html) gene expression microarray database is the largest sequencing analysis database and online data mining tool (24). We used the BRCA vs. normal analysis type and ordered by the underexpression gene rank to analyse target genes. Thresholds were as follows: fold change >1.5, P<0.05 and gene ranking of all.

**UALCAN**

UALCAN (http://ualcan.path.uab.edu/) is a webtool characterized by a user-friendly, comprehensive and interactive platform. It contains data on 31 types of cancer RNA-seq and clinical information from TCGA (25). We used UALCAN to obtain data from TCGA Dataset-Breast Invasive Cancer to analyse and compare the expression of ZNF589 and methylation of its promoter in tumours and normal tissues. ZNF589 expression and promoter methylation-level analyses based on sample types, cancer stages, patient race, age, BRCA subclasses, tumour histology, patient menopausal status and TP53 mutation status were conducted within this portal. P<0.05 was considered statistically significant.

**STRING**

STRING (https://string-db.org/) is a database of known and predicted protein-protein interaction (PPI) information covering 5090 kinds of organisms, and it implements Gene Ontology (GO) and KEGG classification systems (26). We constructed a PPI network with the maximum number of interactors to show no more than 20 interactors in the
Of course, we carried out functional enrichment in our node network and highlighted interested item-associated nodes with specific colours.

**DAVID**

DAVID (https://david.ncifcrf.gov/) is an integrated biological knowledge base aimed at the functional analysis of large gene lists through GO enrichment (27,28). We placed the corresponding genes of the 26 proteins interacting with ZNF589 into the gene list and selected official gene symbols as identifiers. We selected *Homo sapiens* to limit the annotation and designated it as the background.

**cBioPortal**

cBioPortal (http://www.cbiportal.org/) is an online web tool for analysing multidimensional tumour genomics data, and we used it to analyse ZNF589 alterations, such as mutations, copy number variations, fusion, amplification and deep deletion (29).

**K-M plotter**

We used K-M plotter (www.kmplot.com) to assess the prognostic value of ZNF589 on survival in BRCA. Containing 21 types of cancer, K-M plotter includes gene chip and RNA-seq data sources from GEO, TCGA and EGA (30).

**LinkedOmics**

LinkedOmics (http://www.linkedomics.org/login.php) is an online platform that permits researchers to analyse 32 TCGA cancer-associated and multidimensional datasets (31). We used the invasive breast carcinoma cohort and selected TCGA_BRC in the HiSeq RNA platform for the search dataset and target dataset, and the Pearson correlation test was used as the statistical method for assessing ZNF589. The LinkFinder module was used to explore ZNF589 co-expression genes. The results are presented graphically in volcano plots, heat maps and scatter plots. The LinkInterpreter module was used with the Gene Set Enrichment Analysis (GSEA) tool to carry out GO biological process enrichment and KEGG pathway enrichment of co-expressed genes of ZNF589. P value was the rank criteria, the minimum number of genes was 3, and 500 simulations were conducted.

**Bioinformatics**

Bioinformatics (http://www.bioinformatics.com.cn/) is a free online visualization tool for bioinformatics data. We used the Enrichment Dot Bubble module to upload the genes from the LinkedOmics and STRING analysis results. The data format was directed by the online data template.

**KEGG**

KEGG (https://www.kegg.jp/kegg/) is an online database resource for determining biology functions at the molecular level. We used its pathway module to determine the locations of interesting genes in specific molecular pathways. Target genes were highlighted by the user data mapping function. The KEGG orthologue number of genes was searched in an orthologue table.

**GSEA**

GSEA is a computational method that checks whether a set of genes are enriched at the top or bottom of a specific ranked list of genes (32,33). We used GSEA 4.0.3 to analyse 20,530 genes in the TCGA genomic matrix grouped by the median ZNF589 expression level. c2.cp.kegg.v7.1.symbols.gmt was selected as the reference gene set, and FDR <0.25 was considered statistically significant.

**Statistical analysis**

Comparisons of the transcription level of ZNF589 between normal tissue and BRCA groups in the TCGA and Oncomine datasets were conducted through paired/unpaired t-tests. Survival plots from TCGA and K-M plotter were performed by a log-rank test along with the hazard ratio (HR) with 95% confidence interval. To analyse the OS, RFS and post-progression survival of BRCA patients, the samples were split by the median cut-off of ZNF589 expression and assessed by a K-M survival plot along with the HR with 95% confidence interval and log-rank P value. All statistical analyses were performed using SPSS 26.0 software (SPSS, Inc., Chicago, IL, USA), and P<0.05 was considered statistically significant.

**Results**

**Expression level of ZNF589 was downregulated in BRCA patients**

To compare the differences in expression between tumour
and normal tissue, we analysed the transcriptional level of ZNF589 in unpaired (P<0.0001) (Figure 1A) and paired (P<0.0001) (Figure 1B) samples. We found that ZNF589 was downregulated in BRCA tumour tissue from the TCGA cohort. To test this result in another way, we downloaded the transcriptional data of ZNF589 from the Oncomine database and compared the expression differences between tumour and normal tissues. As expected, we found that the expression of ZNF589 was downregulated in ductal breast carcinoma according to Sorlie breast research (P=0.005) (Figure 1C) and Sorlie breast 2 research (P=0.0019) (Figure 1D), and it was also downregulated in invasive breast carcinoma in Finak breast research (P<0.0001) (Figure 1E). These results indicated that ZNF589 was downregulated in BRCA.

**Figure 1** ZNF589 expression was significantly downregulated in BRCA. (A) The relationship of ZNF589 expression level between BRCA tissue with unpaired normal breast tissue from TCGA cohort. (B) The relationship of ZNF589 expression level between BRCA tissue with adjacent normal breast tissue in a paired way from TCGA cohort. (C) The expression of ZNF589 between normal breast tissue and ductal breast carcinoma in Sorlie breast research from Oncomine database. (D) The expression of ZNF589 between normal breast tissue and ductal breast carcinoma in Sorlie breast 2 research from Oncomine database. (E) The expression of ZNF589 between normal breast tissue and invasive breast carcinoma in Finak breast research from Oncomine database. **, P<0.01; ****, P<0.0001. BRCA, breast cancer.
To further explore the expression variance, we used clinical parameters as the classification factors. We found that ZNF589 was downregulated in all cancer stages of BRCA (Figure 2A). For the molecular subclasses, downregulation was found in the luminal, HER2-positive and triple-negative subgroups. In particular, the HER2-positive subtype expressed the lowest level, followed by the triple-negative subtype (luminal vs. HER2-positive, luminal vs. TNBC and HER2-positive vs. TNBC were statistically significant and P value <0.05) (Figure 2B). To explore the correlation between expression and hormone receptor status, we analysed the high- and low-expression rates in different hormone receptor statuses with the chi-square test. We found that the high expression rate of the ER-negative and PR-negative groups was lower as well as the HER2-positive group; in other words, ZNF589 was downregulated in the ER-negative (P<0.001) (Figure S1A), PR-negative (P<0.001) (Figure S1B) and HER2-positive (Figure S1C) groups and ZNF589 expression was correlated with hormone status. To investigate expression differences in different races, we compared three major patients based on race and found that tumour tissues in all races were downregulated; moreover, African Americans
and Asians had the lowest levels compared with Caucasians (Caucasian vs. African Americans and Caucasian vs. Asians were statistically significant and P value <0.05) (Figure 2C). We also analysed different menopausal statuses and found statistically significant differences among premenopausal, perimenopausal and postmenopausal patients compared to normal controls (Figure 2D). Moreover, ZNF589 was downregulated in all age groups (Figure 2E), and to further investigate the relationship between expression and patient age, we artificially set the usual age of 55 as the cut-off and defined <55 as the high-risk group and ≥55 as the low-risk group. Interestingly, we found that the high ZNF589 expression rate was upregulated in the low-risk group and that ZNF589 expression was correlated with age status (Figure S1D). We also separated patients into the TP53-mutant group and TP53-nonmutant group. It is universally acknowledged that TP53 mutation correlates to a high risk of oncogenesis. In this case, we found that both groups were downregulated and that the TP53-mutant group was the lowest (Figure 2F). These results indicated that ZNF589 was usually expressed at lower levels in the high-risk subgroup of people.

**Downregulation of ZNF589 predicts poor OS in BRCA patients**

To investigate the prognostic value of ZNF589, we used the TCGA database to conduct the survival analysis. According to the total OS result, patients with high ZNF589 expression showed a higher OS rate (P=0.047) (Figure 3A). We artificially defined pathological stages I to II as early stages and stages III to IV as terminal stages. Although the OS of the early stage was not obviously changed (P=0.575) (Figure 3B), high ZNF589 led to better OS in terminal stage (P=0.0249) (Figure 3C). As a result, we further explored the survival rate of OS in different hormone statuses to determine the prognosis in specific types. Significant results were observed for PR-negative-BRCA patients (Figure 3D).
negative status (P=0.0002) (Figure 3D) but not ER-negative (P=0.0999) (Figure S2A) or HER2 negative (P=0.6981) (Figure S2B). Considering that OS was different in PR-negative BRCA, we analysed the OS of triple-negative BRCA; however, the number of accessible cases was too low to analyse. For triple-negative BRCA, it overlapped with basal-like BRCA. We used K-M plotter to analyse the association between ZNF589 expression and the clinical outcome in OS of basal-like BRCA. Surprisingly, the result was statistically significant (Figure S2C).

Furthermore, univariate and multivariate Cox regression models were used to assess the prognostic value of ZNF589 (Table 1). What stood out in the table was that ZNF589 expression (low vs. high) was one of independent prognostic factors (HR =0.56, P=0.021), which included age (≤55 vs. >55 years) (HR =1.67, P=0.005**), lymph node metastasis (N0 vs. N1–3) (HR =2.11, P=0.000**), distant metastasis (M0 vs. M1) (HR =3.82, P=0.000**), TNM stage (I–II vs. III–IV) (HR =2.01, P=0.000**), and ZNF589 expression (low vs. high) (HR =0.69, P=0.038*).

**Table 1 Univariate and multivariate OS analysis of prognostic factors for BRCA patients (n=1,052)**

<table>
<thead>
<tr>
<th>Clinicopathologic parameters</th>
<th>OS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Univariate analysis</td>
</tr>
<tr>
<td></td>
<td>HR</td>
</tr>
<tr>
<td>Age (≤55 vs. &gt;55 years)</td>
<td>1.67</td>
</tr>
<tr>
<td>Histological (IDC vs. ILC)</td>
<td>1.56</td>
</tr>
<tr>
<td>ER status (positive vs. negative)</td>
<td>0.72</td>
</tr>
<tr>
<td>PR status (positive vs. negative)</td>
<td>0.71</td>
</tr>
<tr>
<td>HER2 status (positive vs. negative)</td>
<td>1.05</td>
</tr>
<tr>
<td>Tumour infiltration (T1–T2 vs. T3–T4)</td>
<td>1.23</td>
</tr>
<tr>
<td>Lymph node metastasis (N0 vs. N1–3)</td>
<td>2.11</td>
</tr>
<tr>
<td>Distant metastasis (M0 vs. M1)</td>
<td>3.82</td>
</tr>
<tr>
<td>TNM stage (I–II vs. III–IV)</td>
<td>2.01</td>
</tr>
<tr>
<td>ZNF589 expression (low vs. high)*</td>
<td>0.69</td>
</tr>
</tbody>
</table>

* using median H-score values as cutoff. *, P<0.05; **, P<0.01; ***, P<0.001. OS, overall survival; BRCA, breast cancer; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, oestrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.

**Downregulation of ZNF589 predicts poor RFS in BRCA patients**

To further explore the prognostic value of ZNF589 in BRCA, we analysed the association between ZNF589 expression and clinical outcomes in RFS (P=0.0043) (Figure 4). The results showed that high expression of ZNF589 predicted better RFS in BRCA patients. Similarly, we artificially defined the early stage and the terminal stage as OS. Although the RFS of the early stage was not obviously distinguished (P=0.1580) (Figure 4B), high ZNF589 led to better RFS in the terminal stage (P=0.0090) (Figure 4C). In these cases, we explored RFS in different histological subtypes and found that high ZNF589 expression significantly predicted better prognosis in invasive ductal carcinoma (IDC) (P=0.0091) (Figure S2D). While the RFS of the IDC early stage was not obviously significant (P=0.5214) (Figure S2E), high ZNF589 corresponded to better RFS in terminal stage (P=0.0045) (Figure S2F).

Hormone status was also considered in the RFS analysis. The single most striking observation to emerge from the data comparison was that better prognosis was found in ER-negative (P=0.0129) (Figure 4D), PR-negative (P=0.0130) (Figure 4E) and HER2-negative BRCA (P=0.0002) (Figure S2G). The triple-negative molecular subtype was assessed, and the same trend was statistically significant (P=0.0052) (Figure 4F). These results indicated that ZNF589 is a potential prognostic factor, especially in advanced stages, and has IDC subtype specificity in RFS.

For RFS, univariate and multivariate Cox regression models were again used to assess the prognostic value of
Table 2) and revealed that ZNF589 expression (low vs. high) was one of the independent prognostic factors (HR =0.43, P=0.017), which included PR status (positive vs. negative) (P=0.015), tumour infiltration (T1–T2 vs. T3–T4) (P=0.047), lymph node metastasis (N0 vs. N1–3) (P<0.001), distant metastasis (M0 vs. M1) (HR =5.06, P=0.003) and AJCC TNM stage (I–II vs. III–IV) (P<0.001).

Figure 4 Downregulation of ZNF589 predicts poor RFS in BRCA patients. The survival curve data was from TCGA database and the survival rate was evaluated by RFS. (A) The total RFS. (B,C) ZNF589 is not important in RFS of early-stage BRCA but significant in terminal period. (D,E) ZNF589 is significant in RFS of ER- and PR-negative BRCA. (F) Low expression of ZNF589 predicts poor RFS in triple-negative BC patients. RFS, relapse-free survival; BRCA, breast cancer; TCGA, The Cancer Genome Atlas; ER, oestrogen receptor; PR, progesterone receptor.

ZNF589 co-expressive genes for probable mechanism in BRCA

To investigate the possible mechanism of oncogenic suppression, we explored ZNF589 co-expression genes through the LinkedOmics database and found that there were 6,904 positively correlated genes and 4,622 negatively correlated genes (FDR <0.05). We then obtained a heatmap
of the top 50 positively and negatively correlated genes from a volcano plot of all ZNF589-associated genes (Figure 5A,B,C). The matched module of LinkedOmics was used to conduct a GSEA to determine the KEGG pathways of associated genes (Figure 5D). To further confirm the previous results, we carried out a GSEA of ZNF589 with KEGG gene sets in BRCA based on the TCGA cohort. There were 1,215 samples and 20,530 genes in the analysis. We divided the 1,215 samples into a High Group and Low Group by the median cut-off value of ZNF589. No significantly enriched gene set was found in the High (H) phenotype, but 8 gene sets were significantly enriched in the Low (L) phenotype at a nominal P value <1%, and 19 gene sets were significantly enriched at a nominal P value <5%. Comparing the results of the LinkedOmics matched GSEA and TCGA cohort GSEA enrichment analysis, we found that there were many KEGG pathways in common and related to tumorigenesis. Because the cell cycle is a conventional research aspect in BRCA, we focused on the cell cycle pathway for the convenience of subsequent experimental research. Remarkably, the cell cycle gene set [ \text{Normalized Enrichment Score (NES)} >1, \text{NOM P value} <0.05, \text{FDR q value} <0.25] was negatively correlated with ZNF589 expression (Figure 5E). There were 50 core enriched genes in the cell cycle gene set (Table S1). For the cell cycle from the KEGG gene set, the top three leading-edge genes were cyclin E1 (CCNE1), polo-like kinase 1 (PLK1), and cyclin B2 (CCNB2). CCNE1 is a member of the cyclin E family and positively related to the G1/S phase transition (34). It has already been demonstrated that deregulated cyclin E induces chromosome instability and drives cells towards more advanced tumour stages (35). PLK1 is a key mediator of the transition of the G2-M phase of the cell cycle, and its inhibition induces mitotic arrest of BRCA (36,37). CCNB2 was first reported to be associated with BRCA prognosis in 2013 and is a member of the cyclin family controlling the G2/M phase transition (38). To provide a better understanding of the location and function of leading-edge genes in the gene set of the cell cycle pathway, we placed the leading-edge genes into the KEGG pathway mapping module (Figure 5F). The results showed that ZNF589 could play an important role during breast tumorigenesis, probably through cell cycle regulation.

### Genome-wide proteins associated with ZNF589 and probable mechanism in BRCA

To explore the possible role of ZNF589 as a tumour suppressor at the protein level, we used the STRING database to analyse the PPI network. As shown in the network, the predicted functional partners were TRIM28, clavesin-1 (CLVS1), ZNF618, NEDD4 binding protein...
Figure 5 ZNF589 co-expressive genes for probable mechanism in BRCA. (A,B) Important positively and negative correlated genes with ZNF589 from LinkedOmics. (C) Volcano plot contains all of ZNF589 associated and statistically significant genes from LinkedOmics. (D) Bubble chart of interested KEGG pathways of ZNF589 associated genes with GO enrichment from LinkedOmics. (E) Cell cycle with GSEA enrichment of ZNF589 from TCGA database. (F) Leading edge genes of cell cycle by GSEA enrichment were labelled by green background and the top ten genes were specially marked by red. BRCA, breast cancer; KEGG, Kyoto Encyclopaedia of Genes and Genomes; GO, Gene Ontology; TCGA, The Cancer Genome Atlas; GSEA, Gene Set Enrichment Analysis.
2 like 1 (N4BP2L1) and transmembrane protein 92 (TMEM92). Considering that only 4 functional partners were predicted, we added the second shell of nodes in the analysis and obtained more indirectly interactive proteins: SUMO-conjugating enzyme UBC9 (UBE2I), E3 ubiquitin-protein ligase Mdm2 (MDM2), cellular tumour antigen p53 (TP53), paired amphipathic helix protein Sin3a (SIN3A), serine-protein kinase ATM (ATM), mediator of DNA damage checkpoint protein 1 (MDC1), TP53-binding protein 1 (TP53BP1), Histone H2AX (H2AFX), histone deacetylase 1 (HDAC1), small ubiquitin-related modifier 1 (SUMO1), cell division cycle 5-like protein (CDC5L), ZNF350, ZNF274, ZNF with KRAB and SCAN domains 7 (ZKSCAN7), etc. (Figure 6A). To determine which BP and KEGG pathways were enriched in these proteins, we performed a web-matched enrichment analysis to obtain a summary of KEGG pathways. We found that these proteins were also related to pathways involved in the cell cycle, and we highlighted these nodes with different colours for each item (Figure 6A). To further confirm this result, we input these interactive protein-related genes into the DAVID online annotation tool to conduct GO enrichment analyses, and important enriched pathways were identified (Figure 6B). Surprisingly, we obtained the cell cycle pathway again, and the leading-edge genes HDAC1, TP53, MDM2 and ATM were placed into the KEGG pathway through the DAVID mapping tool (Figure 6C). These results strongly indicated that ZNF589 probably regulates the cell cycle through a protein-interactive mechanism.

**Downregulation of ZNF589 transcription associated with hypermethylation of its promoter region but not genetic alteration in BRCA**

To determine the reason for ZNF589 downregulation, we investigated the alteration status through cBioPortal (Figure 7A) and hypermethylation of the ZNF589 promoter area through UALCANN. We found that mutations, amplifications and deep deletions of ZNF589 were rare. Statistically, the alteration rate was extremely low. The changes in the relationship between the expression of ZNF589 and its promoter methylation level in the TCGA samples were compared. A significant outcome was obtained: the expression of the primary tumour was downregulated while the promoter methylation level was upregulated (Figure 7B). As the pathological stage advanced, the expression of ZNF589 was downregulated compared to that in normal tissues and the methylation level of ZNF589 was upregulated (Figure 7C). Specifically, the methylation level of all tumour subclasses was upregulated (Figure 7D).

Regarding racial differences, we found the same trend: when the expression of the primary tumour was downregulated, the promoter methylation level was upregulated. We also observed that Asian patients had the highest methylation (Caucasian vs. Asian and African-American vs. Asian were statistically significant and P value <0.05) (Figure 7E). This finding suggested that there might be a racial component to the promoter methylation level of ZNF589. In addition to racial elements and tumour subclasses, we also considered menopausal status (Figure 7F), patient age (Figure 7G) and TP53 mutation (Figure 7H). We observed that the promoter methylation level was upregulated while the expression of the primary tumour was downregulated. We speculated that the demethylation of the ZNF589 promoter area could be a therapeutic target for BRCA patients with low ZNF589 expression.

**Discussion**

ZNF589 is a member of the ZNF family, and its encoded product contains C2H2-type ZNFs and KRAB (5). Its role in tumorigenesis is seldom reported. Herein, we assessed the latent role of ZNF589 in breast carcinogenesis. Our study found for the first time that epigenetic silencing of ZNF589 was associated with poor OS and RFS in BRCA. The Cox regression results suggested that ZNF589 could act as an independent prognostic biomarker for BRCA. Further analysis showed that ZNF589 expression was negatively correlated with cell cycle progression at the transcriptional and protein-interactive levels.

Analysis of the transcriptome from different databases for all kinds of parameters confirmed that ZNF589 was downregulated in tumour tissues, which suggested that ZNF589 might be a tumour suppressor (39). The subgroup analysis divided by cancer stage showed that there was a gradual decline in ZNF589 expression, which might be negatively correlated with stage progression or malignancy to some degree. According to the subgroup divided by hormone status, the HER2-positive subtype expressed the lowest level, followed by the triple-negative subtype. Interestingly, HER2 positivity and TNBC are malignant subtypes in clinical practice. Therefore, we assumed that ZNF589 expression was negatively correlated with BRCA malignancy. Furthermore, the correlation analysis indicated that the expression of ZNF589 was downregulated in ER-negative, PR-negative and HER2-positive cells and
Figure 6 ZNF589 interactive proteins for probable mechanism in BRCA. (A) Direct and indirect interactive proteins of ZNF589 and highlighted cell cycle item-associated nodes with specific colour. Query protein ZNF589 was marked by red and the first shell of interactors were highlighted by other colour. Indirect interactive proteins were the second shell of interactors of ZNF589. Each item associated with cell cycle was represented by a kind of colour. Network nodes represent proteins. Splice isoforms or post-translational modifications were collapsed, i.e., each node represents all the proteins produced by a single, protein-coding gene locus. Edges represent protein-protein associations. Associations were meant to be specific and meaningful, i.e., proteins jointly contribute to a shared function; this does not necessarily mean they are physically binding each other. (B) Bubble chart of interested KEGG pathways of ZNF589 interactive proteins from STRING database with DAVID online functional annotation tool through GO enrichment. (C) ZNF589 interactive proteins from STRING database in list of cell cycle genes by DAVID annotation were labeled by red stars. BRCA, breast cancer; KEGG, Kyoto Encyclopedia of Genes and Genomes; GO, Gene Ontology.
**Figure 7** The hypermethylation of ZNF589 rather than genetic alteration may contribute to the downregulation of transcription. (A) Rare genetic alteration was observed from cBioPortal online tool. (B,C,D,E,F,G,H) Methylation level of normal breast tissue for ZNF589 compared with breast solid tumours grouped by (B) sample type, (C) individual cancer stage, (D) subclasses, (E) patient’s race, (F) menopause status, (G) patient’s age and (H) TP53 mutation. *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.
negatively related to BRCA malignancy. In terms of race, the race-specific expression module indicated that the role of ZNF589 might be more significant in specific human races. The menopause results indicated that hormone level changes did not affect the ZNF589 low-expression state.

Low expression of ZNF589 was significantly related to poor OS and RFS (40). The survival trend in OS showed that ZNF589 might be a potential tumorigenic suppressor in BRCA. On the other hand, the survival trend in RFS implied that ZNF589 may play a key role in the suppression of local tumour recurrence. Thus, ZNF589 may play a role in cell proliferation, apoptosis, senescence, pyroptosis and the cell cycle (41-45). Interestingly, OS was statistically significant in basal-like BRCA, while RFS was statistically significant in triple-negative and IDC subtype BRCA. These results hinted that ZNF589 could also play a role in the overall prognosis and local recurrence of specific subtypes of BRCA. However, how ZNF589 acts on tumorigenesis and recurrence remains unclear.

To explore the possible mechanism of ZNF589 in oncogenic repression, we conducted a LinkedOmics matched GSEA and TCGA cohort GSEA enrichment analysis, and we found there were many KEGG pathways in common and related to tumorigenesis, including the proteasome (46,47), oxidative phosphorylation (48,49), vibrio cholerae infection (50,51), Parkinson disease (52,53), protein export (54,55), pathogenic Escherichia coli infection (56,57), N-Glycan biosynthesis (58,59), glycosphingolipid biosynthesis (60,61), glutathione metabolism (62,63), cell cycle (64,65), Alzheimer disease (66,67) and galactose metabolism pathways (68,69). Transcriptionally, we obtained the cell cycle pathway as one of the enriched KEGG pathway, and biological processes were enriched. As a result, ZNF589 may also regulate the cell cycle process through TRIM28 via a protein-interactive method. Thus, we hypothesize that TRIM28 plays a key role in BRCA repression of ZNF589. First, ZNF589 could combine with TRIM28 to transcriptionally regulate downstream genes to arrest the cell cycle. For example, TRIM28 acts as a nuclear corepressor with KZFPs to mediate gene silencing by recruiting chromodomain helicase DNA binding protein 3 (CHD3), which is a subunit of the nucleosome remodelling and deacetylation (NuRD) complex, and SET domain bifurcated histone lysine methyltransferase 1 (SETDB1) specifically methylates histone H3 at ‘Lys-9’ (H3K9me) to the promoter regions of KRAB target genes (14). TRIM28 enhances transcriptional repression by coordinating the increase in H3K9me, the decrease in histone H3 ‘Lys-9’ and ‘Lys-14’ acetylation (H3K9ac and H3K14ac, respectively) and the disposition of heterochromatin protein 1 (HP1) proteins (73,74). Therefore, KZFPs work with TRIM28 to conduct transcriptional repression. Coincidently, ZNF589 was first found to encode a protein containing C2H2-type zinc finger motifs and a Kruppel-associated box (KRAB) domain in a study of haematopoietic stem/progenitor cells (5). Therefore, we assumed that ZNF589 combined with TRIM28 to transcriptionally repress downstream genes. Interestingly, not all STRING-predicted proteins promoted the cell cycle, such as TP53 and SIN3A. Although the complex suppression of these antitumour genes by ZNF589-TRIM28 may contradict the tumour repressing role of ZNF589, the ZNF589-TRIM28 complex might also transcriptionally promote the expression of downstream proteins to repress the cell cycle in an unknown way. Alternatively, ZNF589 probably cooperates with TRIM28 to induce PPI with downstream proteins to repress the cell cycle. TRIM28 itself is an oncogenic gene and promotes proliferation and metastatic progression in BRCA (75). Thus, ZNF589 could possibly regulate the transcription of TRIM28 to exert a tumour-suppressive role.

After exploring the possible oncogenic repression mechanism, we found that ZNF589 was a possible tumour suppressor and a promising biomarker for BRCA. To clarify the reason for the downregulation of ZNF589, we took genetic and epigenetic levels into consideration. Although gene alterations of ZNF589 were rare in BRCA in eBioPortal, we found that the downregulation of ZNF589 was accompanied by high methylation in the ZNF589 promotor area, which was consistent with the comparison of
the UALCAN expression analysis and methylation analysis of ZNF589 in BRCA. Thus, downregulation may not have been caused by gene alteration in the DNA sequence of ZNF589 but by methylation of the ZNF589 transcriptional promoter sequence.

**Limitations**

We used several online analysis tools to obtain the statistics about ZNF589 and reconfirmed these data to ensure the reliability. However, the lack of experimental data introduced uncertainty in our results. Clinical patient tissue could be used to test the mRNA and protein expressional variance of ZNF589 in tumour and normal tissues.

In this study, we systematically analysed the expression and prognostic value of ZNF589 in BRCA. Our analysis predicted that ZNF589 was downregulated and that its promoter region was highly methylated in BRCA patients, especially in terminal patients. Moreover, low expression of ZNF589 was accompanied by poor OS and RFS. Therefore, ZNF589 might be a latent prognostic biomarker in terminal BRCA. Regarding the repressive mechanism of tumorigenesis, ZNF589 may suppress cancer through many important cancer-associated pathways, such as the cell cycle. In conclusion, ZNF589 may be a latent terminal-stage prognostic biomarker and potential treatment target for BRCA patients.

**Acknowledgments**

**Funding:** This work was supported by the National Natural Science Foundation of China (Grant No. 81472482) and the Clinical Technology Innovation and Cultivation Project of Army Military Medical University of China (Grant No. CX2019LC120).

**Footnote**

**Reporting Checklist:** The authors have completed the REMARK reporting checklist. Available at http://dx.doi.org/10.21037/tcr-20-3166

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr-20-3166). The authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and this work did not require a statement on obtaining ethical approval because all data were obtained from public databases.

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

**References**


37. Maire V, Némati F, Richardson M, et al. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of

**Figure S1** The expression of ZNF589 correlated with hormone receptor status and age. The expression of ZNF589 in BRCA tissue grouped by (A) ER status, (B) PR status, (C) HER2 status and (D) age. **, P<0.01; ****, P<0.0001. BRCA, breast cancer; ER, oestrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
Figure S2 The expression of ZNF589 was important in OS for PR negative BRCA, but not in (A) ER and (B) HER2 negative status. ZNF589 expression may be a relapse-free prognostic factor for basal-like BRCA and IDC. (C) Low ZNF589 expression means poor OS in basal-like BC patients and the data was reached from KM plotter database. (D) Low ZNF589 expression means poor RFS in invasive ductal cancer patients. (E,F) They show that ZNF589 is not important in RFS of early-stage IDC but significant in terminal period. (G) The expression of ZNF589 was important in RFS for HER2 negative BC and the data was reached from K-M plotter database. IDC, invasive ductal carcinoma. OS, overall survival; PR, progesterone receptor; BRCA, breast cancer; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; RFS, relapse-free survival; K-M, Kaplan-Meier.
Table S1 GSEA core enrichment genes in cell cycle

<table>
<thead>
<tr>
<th>Gene name</th>
<th>Rank metric score</th>
<th>Running enrichment score</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCNE1</td>
<td>-0.288668424</td>
<td>0.002449723</td>
</tr>
<tr>
<td>PLK1</td>
<td>-0.286605865</td>
<td>-0.0186176</td>
</tr>
<tr>
<td>CCNB2</td>
<td>-0.273230791</td>
<td>-0.03811296</td>
</tr>
<tr>
<td>YWHAQ</td>
<td>-0.25690937</td>
<td>-0.056137748</td>
</tr>
<tr>
<td>YWHAG</td>
<td>-0.255838722</td>
<td>-0.07482749</td>
</tr>
<tr>
<td>CCNA2</td>
<td>-0.247039527</td>
<td>-0.091675065</td>
</tr>
<tr>
<td>MAD2L1</td>
<td>-0.246948376</td>
<td>-0.10978812</td>
</tr>
<tr>
<td>CDC20</td>
<td>-0.241275787</td>
<td>-0.12681669</td>
</tr>
<tr>
<td>CDC45</td>
<td>-0.240181714</td>
<td>-0.14436017</td>
</tr>
<tr>
<td>BUB1</td>
<td>-0.237607449</td>
<td>-0.16118655</td>
</tr>
<tr>
<td>HDAC2</td>
<td>-0.229461938</td>
<td>-0.17581557</td>
</tr>
<tr>
<td>PTTG1</td>
<td>-0.225459203</td>
<td>-0.19156203</td>
</tr>
<tr>
<td>TTK</td>
<td>-0.223908648</td>
<td>-0.20765188</td>
</tr>
<tr>
<td>YWHAH</td>
<td>-0.215837166</td>
<td>-0.22073579</td>
</tr>
<tr>
<td>PKMYT1</td>
<td>-0.21366379</td>
<td>-0.23563205</td>
</tr>
<tr>
<td>MCM6</td>
<td>-0.202016711</td>
<td>-0.24639909</td>
</tr>
<tr>
<td>CDK1</td>
<td>-0.199004576</td>
<td>-0.25949636</td>
</tr>
<tr>
<td>E2F4</td>
<td>-0.198980197</td>
<td>-0.2740875</td>
</tr>
<tr>
<td>CHEK1</td>
<td>-0.194735169</td>
<td>-0.2864722</td>
</tr>
<tr>
<td>CDK4</td>
<td>-0.192257181</td>
<td>-0.29888685</td>
</tr>
<tr>
<td>CCNB1</td>
<td>-0.183446452</td>
<td>-0.30754703</td>
</tr>
<tr>
<td>BUB1B</td>
<td>-0.181066513</td>
<td>-0.31918478</td>
</tr>
<tr>
<td>CDC25B</td>
<td>-0.175188035</td>
<td>-0.32800248</td>
</tr>
<tr>
<td>E2F1</td>
<td>-0.171499342</td>
<td>-0.33785982</td>
</tr>
<tr>
<td>CDC25C</td>
<td>-0.170346707</td>
<td>-0.34974745</td>
</tr>
<tr>
<td>DBF4</td>
<td>-0.166094989</td>
<td>-0.35748526</td>
</tr>
<tr>
<td>PCNA</td>
<td>-0.158068687</td>
<td>-0.3622168</td>
</tr>
<tr>
<td>ANAPC11</td>
<td>-0.154473722</td>
<td>-0.3695443</td>
</tr>
<tr>
<td>MCM5</td>
<td>-0.153699517</td>
<td>-0.37993956</td>
</tr>
<tr>
<td>YWHAZ</td>
<td>-0.150444567</td>
<td>-0.3877305</td>
</tr>
<tr>
<td>MCM2</td>
<td>-0.150441617</td>
<td>-0.39876118</td>
</tr>
<tr>
<td>CDKN2A</td>
<td>-0.149845734</td>
<td>-0.40920374</td>
</tr>
<tr>
<td>CDC6</td>
<td>-0.149303034</td>
<td>-0.4197006</td>
</tr>
<tr>
<td>RBX1</td>
<td>-0.146690831</td>
<td>-0.4277571</td>
</tr>
<tr>
<td>E2F3</td>
<td>-0.137344509</td>
<td>-0.42631385</td>
</tr>
<tr>
<td>Gene name</td>
<td>Rank metric score</td>
<td>Running enrichment score</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>TFDP1</td>
<td>-0.13522853</td>
<td>-0.43349355</td>
</tr>
<tr>
<td>ESPL1</td>
<td>-0.135166824</td>
<td>-0.44340858</td>
</tr>
<tr>
<td>CCND3</td>
<td>-0.133078381</td>
<td>-0.45028162</td>
</tr>
<tr>
<td>CHEK2</td>
<td>-0.13015227</td>
<td>-0.4557768</td>
</tr>
<tr>
<td>E2F2</td>
<td>-0.12944518</td>
<td>-0.46443778</td>
</tr>
<tr>
<td>CDC25A</td>
<td>-0.125626907</td>
<td>-0.46824583</td>
</tr>
<tr>
<td>CDK6</td>
<td>-0.123509049</td>
<td>-0.47363558</td>
</tr>
<tr>
<td>MCM3</td>
<td>-0.119423702</td>
<td>-0.47666547</td>
</tr>
<tr>
<td>CUL1</td>
<td>-0.117711961</td>
<td>-0.48169836</td>
</tr>
<tr>
<td>CDC7</td>
<td>-0.114194013</td>
<td>-0.4836173</td>
</tr>
<tr>
<td>SMC1B</td>
<td>-0.112961881</td>
<td>-0.49003044</td>
</tr>
<tr>
<td>MCM4</td>
<td>-0.11028304</td>
<td>-0.49243397</td>
</tr>
<tr>
<td>CCNE2</td>
<td>-0.109432951</td>
<td>-0.4991972</td>
</tr>
<tr>
<td>SFN</td>
<td>-0.107769698</td>
<td>-0.5039875</td>
</tr>
<tr>
<td>MCM7</td>
<td>-0.104619861</td>
<td>-0.50650024</td>
</tr>
</tbody>
</table>

GSEA, Gene Set Enrichment Analysis.